Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis
Eleni Efstathiou
Fil Manuguid
Peter Kirkpatrick

Showing results (191-200 of 476) with videos related to

Pageof 48
Sort By:
Nature Reviews. Drug Discovery|December 2, 2008
LacosamideEmilio Perucca, Uma Yasothan, Gilbert Clincke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancerShi-Ming Tu, Paul Mathew, Franklin C Wong, et al.
The Journal of Clinical Investigation|July 12, 2008
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanismsZhi Gang Li, Paul Mathew, Jun Yang, et al.
Cancer Genetics and Cytogenetics|May 30, 2002
A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicingAngela Ladopoulou, Irene Konstantopoulou, Sofia Armaou, et al.
Urology|September 8, 2004
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology GroupHelena Linardou, Gerassimos Aravantinos, Eleni Efstathiou, et al.
Urologic Oncology|September 9, 2010
Recurrent seminomas: clinical features and biologic implicationsAvik Som, Rui Zhu, Charles C Guo, et al.
Urologic Oncology|April 10, 2003
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II studyJeri Kim, Randall E Millikan, Terry L Smith, et al.
Medicine|September 13, 2021
The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progressionIoanna Maria Grypari, Souzana Logotheti, Vasiliki Zolota, et al.
Cancer|June 5, 2003
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastasesLance C Pagliaro, Ebrahim S Delpassand, Dallas Williams, et al.
Nature Reviews. Drug Discovery|July 2, 2008
Dabigatran etexilateBengt I Eriksson, Helen Smith, Uma Yasothan, et al.
Pageof 48

Showing results (191-200 of 476) with videos related to

Sort By:
Pageof 48
Nature Reviews. Drug Discovery|December 2, 2008
LacosamideEmilio Perucca, Uma Yasothan, Gilbert Clincke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancerShi-Ming Tu, Paul Mathew, Franklin C Wong, et al.
The Journal of Clinical Investigation|July 12, 2008
Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanismsZhi Gang Li, Paul Mathew, Jun Yang, et al.
Cancer Genetics and Cytogenetics|May 30, 2002
A change in the last base of BRCA1 exon 23, 5586G-->A, results in abnormal RNA splicingAngela Ladopoulou, Irene Konstantopoulou, Sofia Armaou, et al.
Urology|September 8, 2004
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology GroupHelena Linardou, Gerassimos Aravantinos, Eleni Efstathiou, et al.
Urologic Oncology|September 9, 2010
Recurrent seminomas: clinical features and biologic implicationsAvik Som, Rui Zhu, Charles C Guo, et al.
Urologic Oncology|April 10, 2003
Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II studyJeri Kim, Randall E Millikan, Terry L Smith, et al.
Medicine|September 13, 2021
The protein arginine methyltransferases (PRMTs) PRMT1 and CARM1 as candidate epigenetic drivers in prostate cancer progressionIoanna Maria Grypari, Souzana Logotheti, Vasiliki Zolota, et al.
Cancer|June 5, 2003
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastasesLance C Pagliaro, Ebrahim S Delpassand, Dallas Williams, et al.
Nature Reviews. Drug Discovery|July 2, 2008
Dabigatran etexilateBengt I Eriksson, Helen Smith, Uma Yasothan, et al.
Pageof 48